Anusha Yarava
A5067295022- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- COVID-19 Impact on Reproduction
- Long-Term Effects of COVID-19
- Blood groups and transfusion
- Blood donation and transfusion practices
- Psychosomatic Disorders and Their Treatments
- Blood transfusion and management
- COVID-19 and Mental Health
- SARS-CoV-2 detection and testing
- Intracerebral and Subarachnoid Hemorrhage Research
- Bacillus and Francisella bacterial research
- Neurosurgical Procedures and Complications
- Acute Ischemic Stroke Management
Johns Hopkins Medicine
2021-2024
Johns Hopkins University
2021-2024
Polyclonal convalescent plasma may be obtained from donors who have recovered coronavirus disease 2019 (Covid-19). The efficacy of this in preventing serious complications outpatients with recent-onset Covid-19 is uncertain.
The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high levels effectively reduces immunocompetent outpatient hospitalization. Food and Drug Administration currently allows CCP the immunosuppressed. Viral-specific in can range 10- to 100-fold between donors, unlike uniform viral-specific...
Abstract Background The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent when administered before symptoms or laboratory evidence infection. Methods This double-blinded, phase randomized, controlled trial (RCT) compared the and safety prophylactic high titer (≥1:320 by Euroimmun ELISA) with standard plasma. Asymptomatic participants aged ≥18 years close...
ABSTRACT BACKGROUND The efficacy of polyclonal high titer convalescent plasma to prevent serious complications COVID-19 in outpatients with recent onset illness is uncertain. METHODS This multicenter, double-blind randomized controlled trial compared the and safety SARS-CoV-2 placebo control symptomatic adults ≥18 years positive for regardless risk factors disease progression or vaccine status. Participants symptom within 8 days were enrolled, then transfused subsequent day. measured primary...
Convalescent plasma, collected from donors who have recovered a pathogen of interest, has been used to treat infectious diseases, particularly in times outbreak, when alternative therapies were unavailable. The COVID-19 pandemic revived interest the use convalescent plasma. Large observational studies and clinical trials that executed during provided insight into how whereby high levels antibodies against administration early within time course disease are critical for optimal therapeutic...
BACKGROUND. COVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion sufficient to prevent disease progression are not defined.
Abstract Background COVID‐19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS‐CoV‐2 infection. We assessed the safety outpatient CCP transfusions administered during clinical trials. Study Design and Methods analyzed data pertaining to transfusion‐related reactions two randomized controlled trials in U.S. that evaluated efficacy versus control various ambulatory settings. Multivariable logistic regression was used assess...
ABSTRACT BACKGROUND The efficacy of SARS-CoV-2 convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. We hypothesized that CCP might prevent when administered before symptoms or laboratory evidence infection. METHODS This double-blinded, phase 2 randomized, controlled trial (RCT) compared the and safety prophylactic high titer (≥1:320) with standard plasma. Asymptomatic participants aged ≥18 years close contact exposure to a person confirmed...
Stereotactic thrombolysis reduces intracerebral haemorrhage (ICH) volume in patients with spontaneous ICH. Whether intrahaematomal alteplase administration is associated a change intraventricular (deltaIVH) and functional outcomes unknown.
Abstract Background Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) reduces hospitalizations among outpatients treated early after symptom onset. It is unknown whether CCP time to resolution outpatients. Methods We evaluated at day 14 by trial arm using an adjusted subdistribution hazard model, with hospitalization as a competing risk. also assessed the prevalence of clusters between treatments. Clusters were defined based on biologic clustering, impact ability work, and...
ABSTRACT BACKGROUND The COVID-19 convalescent plasma (CCP) viral specific antibody levels that translate into recipient post-transfusion sufficient to prevent disease progression is not defined. METHODS This secondary analysis correlated donor and hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double blind, randomized clinical trial compared control plasma. majority of arm hospitalizations (15/17, 88%) occurred in this subgroup. A functional...
In response to the COVID-19 pandemic, we rapidly implemented a plasma coordination center, within two months, support transfusion for outpatient randomized controlled trials. The center design was based on an investigational drug services model and Food Drug Administration-compliant database manage blood product inventory trial safety. A core team adapted cloud-based platform randomize patient assignments track distribution of control high-titer convalescent different groups from 29 donor...
The ongoing evolution of SARS-Co-V2 variants to omicron severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. Covid-19 convalescent plasma (CCP) qualified for high levels effectively reduces immunocompetent outpatient hospitalization. FDA currently allows CCP the immunosuppressed. Viral specific in can range ten-to hundred-fold between donors unlike uniform viral dosing. Limited data on efficacy polyclonal neutralize variants. We examined...
The relevance of preexisting immunity to the four endemic human coronaviruses in first week COVID-19 illness on outcome progression stems from high prevalence ehCoV and SARS-CoV-2 coronaviruses. question has been raised whether therapeutic convalescent plasma or control containing antibodies might alter hospitalization.